TWD 66.3
(-2.21%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 228.25 Million TWD | 452.45% |
2022 | 41.31 Million TWD | 148.19% |
2021 | 16.64 Million TWD | -84.78% |
2020 | 109.36 Million TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | 225.63 Million TWD | -1.15% |
2024 Q2 | 219.72 Million TWD | -2.62% |
2023 FY | 228.25 Million TWD | 452.45% |
2023 Q3 | 130.64 Million TWD | -2.48% |
2023 Q2 | 133.96 Million TWD | 258.09% |
2023 Q1 | 37.41 Million TWD | 141.12% |
2023 Q4 | 228.25 Million TWD | 74.71% |
2022 Q4 | 15.51 Million TWD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Allied Biotech Corporation | 796.6 Million TWD | 71.346% |
GeneFerm Biotechnology Co., Ltd. | 152.07 Million TWD | -50.091% |
Easywell Biomedicals, Inc. | 386.34 Million TWD | 40.919% |
TTY Biopharm Company Limited | 1.91 Billion TWD | 88.081% |
Synmosa Biopharma Corporation | 2.43 Billion TWD | 90.645% |
Orient EuroPharma Co., Ltd. | 4.84 Billion TWD | 95.286% |
Center Laboratories, Inc. | 5.62 Billion TWD | 95.941% |
Tien Liang BioTech Co., Ltd. | 84.65 Million TWD | -169.619% |
Orient Pharma Co., Ltd. | 716.92 Million TWD | 68.162% |
InnoPharmax Inc. | 21.49 Million TWD | -961.71% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 160.83 Million TWD | -41.924% |
Excelsior Biopharma Inc. | 377.4 Million TWD | 39.519% |
DV Biomed Co., Ltd. | 387.69 Million TWD | 41.125% |
Handa Pharmaceuticals, Inc. | 13.24 Million TWD | -1623.995% |
UniPharma Co., Ltd. | 277 Thousand TWD | -82303.249% |
Anxo Pharmaceutical Co., Ltd. | 787.84 Million TWD | 71.027% |
Alar Pharmaceuticals Inc. | 1.4 Million TWD | -16099.929% |
Winston Medical Supply Co., Ltd. | 107.32 Million TWD | -112.67% |
Mercury Biopharmaceutical Corporation | 42.34 Million TWD | -438.99% |
Bioray Biotech Co., Ltd | 69.79 Million TWD | -227.053% |
TSH Biopharm Corporation Limited | 7.84 Million TWD | -2810.328% |